Last post Thu, Apr 17 2008 6:19 PM by runaround. 3 replies.
GW Phamaceuticals said its pioneering cannabis-based medicine failed to show significant improvement in a final stage trial to treat neuropathic pain in multiple sclerosis (MS) patients.
GW said Sativex had a very high patient response rate in the trial but that the results narrowly failed to reach statistical significance due to an unexpectedly large placebo response.
"While valid, this indicates that the effect of Sativex is marginal, and we retain our doubts as to whether the product will ever prove a commercial success," KBC Peel Hunt analyst Paul Cuddon wrote in a research note.
Nomura analyst Gary Waanders described the result as disappointing............. For the full report please go to MSRC: MS Research News : Drugs : Sativex
I'm glad to see we're even able to read about studies that are close but not statistically sig. There was (IMO) a negative trend in the research for quite some time that only the significant studies were discussed...that doesn't tell us much about what's been tried.
I'm interested in why such a large placebo response...any ideas Squiffy?
hi Kara
I think the large placebo response was due to the MSers believing they were getting the "real thing" and illustrates the power of mind over matter...................just my humble opinion. :O)
squiffs
I could not agree with you more.
